Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15957753 | 0.90 | ESR1 (0.63) | ESR1ESR2PDE10ALMNAMAPK1 | |
| SCHEMBL1666112 | 0.88 | PDE10A (0.53) | ESR1ESR2PDE10ALMNAMAPK1 | |
| SCHEMBL12605331 | 0.87 | ESR1 (0.60) | ESR1ESR2PDE10ALMNAMAPK1 | |
| SCHEMBL12605635 | 0.86 | ESR1 (0.54) | ESR1ESR2PDE10ALMNAMAPK1 | |
| SCHEMBL1664551 | 0.86 | PDE10A (0.50) | ESR1ESR2PDE10ALMNAMAPK1 | |
| SCHEMBL1663473 | 0.84 | LMNA (0.63) | PDE10ALMNATSHRXBP1HTT | |
| SCHEMBL1663442 | 0.84 | ESR1 (0.50) | ESR1ESR2PDE10ALMNAMAPK1 | |
| SCHEMBL1664004 | 0.82 | ESR1 (0.84) | ESR1LMNAHTTNPSR1TRPV1 | |
| SCHEMBL10446406 | 0.81 | ESR1 (0.50) | ESR1ESR2PDE10ATRPV1SMN1; SMN2 | |
| SCHEMBL1663008 | 0.81 | ESR1 (0.53) | ESR1ESR2PDE10ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102653-B2 | Substituted quinazolinones as vanilloid antagonists | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102653-B2 | Substituted quinazolinones as vanilloid antagonists | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140315932-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140315932-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8809528-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809528-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | CHEN WEICHUN (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | CHEN WEICHUN (US) | 2013-03-07 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| CN-101356160-A | Trisubstituted quinazolinone derivatives as vanilloid antagonists | JANSSEN PHARMACEUTICA NV (CH) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080194595-A1 | Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2008-08-14 | — | — | US | disclosed |
| US-20080194595-A1 | Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2008-08-14 | — | — | US | disclosed |
| EP-1755606-B1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194595-A1 | Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders | CACNA1A, ALPI, CACNA1E | ESR1 2832/4885ESR2 2694/4885PDE10A 963/4885 |
| US-20140315932-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, TRPV3, CACNA1A | ESR1 2643/4885ESR2 3042/4885PDE10A 1261/4885 |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | ESR1 1321/4885ESR2 2159/4885PDE10A 1942/4885 |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, KCNJ2, TRPV3 | ESR1 3801/4885ESR2 3664/4885PDE10A 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.